{"slideshow_credits": null, "snippet": "We need to evaluate whether new drugs are really worthwhile, because the costs are widely, although perhaps invisibly, shared.", "abstract": "Op-Ed article by Dr Ezekiel J Emanuel contends debate over price of pharmaceuticals should focus on both question of medical value delivered by any given drug, and whether that value can be linked to its price; holds Americans resistant to government regulation may have far fewer objections if they realize just how high insurance premiums can go if drug manufacturers are allowed to continue to set astronomical prices for new classes of drugs. ", "section_name": "Opinion", "print_page": "9", "document_type": "article", "byline": {"person": [{"lastname": "EMANUEL", "rank": 1, "firstname": "Ezekiel", "role": "reported", "organization": "", "middlename": "J."}], "original": "By EZEKIEL J. EMANUEL"}, "web_url": "http://www.nytimes.com/2015/11/08/opinion/sunday/i-am-paying-for-your-expensive-medicine.html", "lead_paragraph": "We need to evaluate whether new drugs are really worthwhile, because the costs are widely, although perhaps invisibly, shared.", "headline": {"print_headline": "I Am Paying for Your Expensive Medicine", "main": "I Am Paying for Your Expensive Medicine", "content_kicker": "Contributing Op-Ed Writer", "kicker": "Op-Ed | Ezekiel J. Emanuel"}, "_id": "563e576538f0d85411acb1d1", "word_count": "1080", "multimedia": [{"height": 126, "url": "images/2013/10/04/opinion/Emanuel-contributor/contibutors-images-slide-KQ7U-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/10/04/opinion/Emanuel-contributor/contibutors-images-slide-KQ7U-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 600, "url": "images/2013/10/04/opinion/Emanuel-contributor/Emanuel-contributor-articleLarge-v2.jpg", "legacy": {"xlarge": "images/2013/10/04/opinion/Emanuel-contributor/Emanuel-contributor-articleLarge-v2.jpg", "xlargewidth": "600", "xlargeheight": "600"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/10/04/opinion/Emanuel-contributor/Emanuel-contributor-thumbStandard-v2.jpg", "legacy": {"thumbnail": "images/2013/10/04/opinion/Emanuel-contributor/Emanuel-contributor-thumbStandard-v2.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-11-08T00:00:00Z", "source": "The New York Times", "news_desk": "OpEd", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Health Insurance and Managed Care", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Regulation and Deregulation of Industry", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": "Sunday Review", "type_of_material": "Op-Ed"}